U.S. External Counterpulsation Devices Market (By Product: Pneumatic ECP Devices, Electrocardiogram (ECG)-Synchronized; By End-use: Hospitals, Cardiac Centers) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The U.S. external counterpulsation devices market size was estimated at USD 163.04 million in 2023 and it is expected to surpass around USD 340.75 million by 2033, poised to grow at a CAGR of 7.65% from 2024 to 2033.

Key Pointers

• In 2023, the pneumatic ECP devices segment held a dominant the market with a share of 37%. 
• The hospital segment dominated the market with a share of 37% in 2023.
• The cardiac center segment is anticipated to witness the highest CAGR of 8.54% from 2024 to 2033.

U.S. External Counterpulsation Devices Market Overview

External counterpulsation (ECP) devices have emerged as a promising non-invasive therapy for cardiovascular conditions, offering patients an alternative to traditional treatments like medications and invasive procedures. In the United States, the market for ECP devices has witnessed significant growth in recent years, driven by factors such as increasing prevalence of cardiovascular diseases, technological advancements, and growing preference for minimally invasive therapies.

U.S. External Counterpulsation Devices Market Growth Factors 

The growth of the U.S. external counterpulsation devices market is propelled by an increasing prevalence of cardiovascular diseases, driven by factors such as sedentary lifestyles and aging population, creates a growing patient pool seeking effective treatment options. Secondly, the rising awareness among both patients and healthcare professionals about the benefits of external counterpulsation therapy contributes to higher adoption rates. Additionally, technological advancements in ECP devices, such as improved efficacy, portability, and user-friendly features, enhance their appeal and usability. Moreover, favorable reimbursement policies and government initiatives aimed at promoting cardiovascular health further stimulate market growth.

Report Scope of the U.S. External Counterpulsation Devices Market

U.S. External Counterpulsation Devices Market Trends:

• Increasing prevalence of cardiovascular diseases, including coronary artery disease and heart failure, is driving demand for non-invasive treatment options like external counterpulsation therapy.
• Growing awareness among patients and healthcare professionals about the efficacy and benefits of external counterpulsation devices as a treatment modality for cardiovascular conditions.
• Rising adoption of digital health technologies, including remote monitoring and data analytics, to optimize the delivery and management of ECP therapy.
• Expansion of reimbursement coverage for external counterpulsation therapy by insurance providers and government healthcare programs, facilitating greater access to treatment for patients.
• Increasing research and development activities focused on improving the safety, efficacy, and patient outcomes associated with external counterpulsation devices.
• Collaborative efforts between industry players, healthcare providers, and regulatory agencies to establish standardized protocols, guidelines, and quality standards for ECP therapy delivery and device manufacturing.

Product Insights

In 2023, the pneumatic ECP devices segment held a dominant the market with a share of 37%. These devices utilize air pressure to enhance blood flow to the heart. They have gained traction due to their proven effectiveness in reducing symptoms in angina and refractory angina pectoris patients. Their non-invasive nature and cost-effectiveness make them appealing to patients and healthcare providers, driving increased demand. The rising prevalence of cardiovascular diseases fuels the growth of the pneumatic ECP devices segment. In addition, ongoing technological advancements further contribute to its market expansion, making it a promising therapeutic option for cardiac patients.

The Enhanced External Counterpulsation (EECP) devices segment is expected to exhibit the highest CAGR during the forecast period. The growth is attributed to its demonstrated effectiveness in improving cardiac function and coronary circulation, making it a preferred choice for treating cardiovascular conditions. The non-invasive and safe nature of EECP therapy attracts patients seeking alternative treatments.

Moreover, continuous technological advancements and increasing clinical evidence position EECP Devices to meet the growing demand for effective non-invasive cardiovascular treatments. According to a study by the American College of Cardiology Foundation (published on February 14, 2023), long-term COVID-19 patients with and without coronary artery disease experienced significant improvement in symptoms after receiving 15–35 hours of EECP therapy.

End-use Insights

Based on end-use, the U.S. ECP devices market is classified into hospitals and cardiac centers & clinics. The hospital segment dominated the market with a share of 37% in 2023Hospitals dominate the ECP devices market due to their larger patient volumes, specialized care for cardiovascular diseases, and access to advanced resources and technologies.

Moreover, with comprehensive treatment options provided by experienced medical professionals, hospitals are the preferred choice for patients seeking ECP therapy. The adoption of ECP therapy, particularly for managing congestive heart failure, exemplifies hospitals' dominance, supported by dedicated cardiology departments and intensive care units. As cardiovascular diseases continue to rise, the demand for ECP devices in hospitals is expected to reinforce their market dominance.

The cardiac center segment is anticipated to witness the highest CAGR of 8.54% during the forecast period. Cardiac centers are specialized healthcare facilities dedicated to the diagnosis and treatment of cardiovascular conditions. They often have advanced medical equipment, specialized staff, and expertise in managing cardiac diseases, including the implementation of ECP therapy.Additionally, as the awareness and recognition of ECP therapy's benefits continue to grow, cardiac centers are increasingly incorporating ECP devices into their treatment protocols. This trend is driven by the effectiveness of ECP therapy in managing various cardiovascular conditions, such as angina and heart failure.

U.S. External Counterpulsation Devices Market Key Companies

• Vaso Corporation
• ACS Diagnostics
• Scottcare Corporation
• Cardiomedics Inc

U.S. External Counterpulsation Devices Market Segmentations:

By Product 

• Pneumatic ECP Devices
• Electrocardiogram (ECG)-Synchronized ECP Devices
• Enhanced External Counterpulsation (EECP) Devices

By End-use 

• Hospitals
• Cardiac Centers